Evidence map›Paper›PMID 41251745›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Baseline PARP-1 PET imaging in patients with advanced solid tumors with DNA damage response mutations.

Tarek Daoud, Jiansong Chen, Peng Wei, Franklin Wong, Timothy A Yap, Lilie L Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tarek DaoudDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Unit 1422, 1515 Holcombe Blvd, Houston, Houston, TX, 77030, USA.
Jiansong ChenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peng WeiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Franklin WongDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Timothy A YapDepartment of Investigational Cancer Therapeutics (Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lilie L LinDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Unit 1422, 1515 Holcombe Blvd, Houston, Houston, TX, 77030, USA. LLLin@mdanderson.org.ORCID 0000-0001-7681-8966

Funding

A novel PARP inhibitor PET tracer for breast cancerR01CA249329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, LILIE LEMING, PIWNICA-WORMS, DAVID · 2021 to 2023
$748k
NCI NIH HHS R01CA249329
6 · The paper itself

Abstract

purposeInhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme with numerous roles in DNA damage response signaling, represent a class of anti-cancer drugs approved for treating solid tumors with defects in the DNA damage response. However, additional methods for identifying patients who would benefit from the use of PARP inhibitors are urgently needed. We evaluated a novel radiotracer,

methodsFifty-two patients with solid tumors underwent whole-body (skull base to thigh) [

resultsUptake of [

conclusions[

Indexed as

DNA DamageMutationNeoplasmsPoly (ADP-Ribose) Polymerase-1Positron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleFluorine RadioisotopesHumansMaleMiddle AgedPoly(ADP-ribose) Polymerase InhibitorsFluorine RadioisotopesPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase Inhibitors[18F]FluorThanatraceBRCAFTTPARP inhibitorsPET imaging biomarker

Identifiers

PMID41251745
PMCPMC13013147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.